Marina Papoutsaki

Athens, ESYE31, Greece

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 29 publications

Drug survival of bimekizumab, guselkumab, and risankizumab after secondary IL-17 inhibitor failure.

Drug survival of bimekizumab, guselkumab, and risankizumab after secondary IL-17 inhibitor failure.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: May 05, 2026

Beyond Clinical Trials: Experience with Bimekizumab in 3 Challenging Cases of Psoriatic Arthritis.

Beyond Clinical Trials: Experience with Bimekizumab in 3 Challenging Cases of Psoriatic Arthritis.

Journal: Mediterranean journal of rheumatology

Published: November 07, 2025

Long-Term Outcomes of Guselkumab and Risankizumab for the Management of Moderate-to-Severe Psoriasis in the Elderly: Results from a Real-World Retrospective Study.

Long-Term Outcomes of Guselkumab and Risankizumab for the Management of Moderate-to-Severe Psoriasis in the Elderly: Results from a Real-World Retrospective Study.

Journal: Journal of clinical medicine

Published: July 25, 2025

Effects of IL17/23 Inhibitors on Markers of Subclinical Atherosclerosis in Patients with Psoriasis: An Observational Study.

Effects of IL17/23 Inhibitors on Markers of Subclinical Atherosclerosis in Patients with Psoriasis: An Observational Study.

Journal: Dermatology and therapy

Published: July 10, 2025

Long-term effectiveness, safety and prognostic factors of response to treatment with bimekizumab in patients with plaque psoriasis: results from a real-world multicentre study.

Long-term effectiveness, safety and prognostic factors of response to treatment with bimekizumab in patients with plaque psoriasis: results from a real-world multicentre study.

Journal: Clinical and experimental dermatology

Published: May 12, 2025

Guselkumab Is Effective for the Management of Scalp Psoriasis in Both Biologic-Naïve and Biologic-Experienced Patients: Results From a Real-World, Retrospective Study.

Guselkumab Is Effective for the Management of Scalp Psoriasis in Both Biologic-Naïve and Biologic-Experienced Patients: Results From a Real-World, Retrospective Study.

Journal: International journal of dermatology

Published: March 28, 2025

Switching from intravenous to subcutaneous infliximab in patients with immune mediated diseases in clinical remission.

Switching from intravenous to subcutaneous infliximab in patients with immune mediated diseases in clinical remission.

Journal: Frontiers in medicine

Published: February 25, 2025

Pyoderma Gangrenosum in a Patient with Crohn's Disease Treated with Adalimumab: A Case-Based Review and Systematic Review of the Current Literature.

Pyoderma Gangrenosum in a Patient with Crohn's Disease Treated with Adalimumab: A Case-Based Review and Systematic Review of the Current Literature.

Journal: Clinics and practice

Published: January 29, 2025

Bimekizumab Treatment for Scalp Psoriasis: A 52-Week, Real-World, Retrospective Study.

Bimekizumab Treatment for Scalp Psoriasis: A 52-Week, Real-World, Retrospective Study.

Journal: International journal of dermatology

Published: November 21, 2024

Single-center experience with bimekizumab in psoriasis patients with previous exposure to interleukin-17 inhibitors.

Single-center experience with bimekizumab in psoriasis patients with previous exposure to interleukin-17 inhibitors.

Journal: International journal of dermatology

Published: October 03, 2024

Risankizumab in obese patients with moderate-to-severe plaque psoriasis: a 104-week, real-world, retrospective study.

Risankizumab in obese patients with moderate-to-severe plaque psoriasis: a 104-week, real-world, retrospective study.

Journal: Archives of dermatological research

Published: July 20, 2024

Switching within the class of IL-17 inhibitors for the treatment of plaque psoriasis: A real-world retrospective study.

Switching within the class of IL-17 inhibitors for the treatment of plaque psoriasis: A real-world retrospective study.

Journal: The Australasian journal of dermatology

Published: June 27, 2024

Showing 1-12 of 29

Last Updated: 09/26/2026